Back Ph. Eur. Commission consults stakeholders on revised Raman spectroscopy chapter

European Pharmacopoeia Department (EPD) Strasbourg, France 22/06/2020
  • Diminuer la taille du texte
  • Augmenter la taille du texte
  • Imprimer la page
  • Imprimer en PDF

The European Pharmacopoeia (Ph. Eur.) is seeking feedback on revised chapter 2.2.48 on Raman Spectroscopy.

Raman spectrometers are increasingly deployed in the pharmaceutical environment. Offering user-friendly interfaces and rapid, non-destructive measurements generating essential information about the sample, their popularity has been further increased by the development of handheld, automated instruments.

Recent technological developments in the field have prompted revision of the current chapter, focusing on aspects that enhance the reliability of the results obtained. For example:

  • the section on response-intensity scale has been updated;
  • a new section on spectral resolution using calcium carbonate has been introduced;
  • procedures for the comparison of spectra are now described.

Moreover, the attention of users has been drawn to the necessity to preferentially select instruments enabling access to data, spectra, control and measurement settings in general. Raman measurement details should be accessible, manageable and understandable.

The revised chapter is published in Pharmeuropa 32.3 for public consultation from July to September 2020. All interested users are strongly encouraged to review the draft and submit their comments. For more information on how to comment, please consult our guide.

In view of the current situation faced by users in areas affected by COVID-19, the European Pharmacopoeia strongly recommends that users who wish to provide comments on a Pharmeuropa text, but who are unable to do so before the end of the commenting period, contact their National Pharmacopoeia Authority (NPA) in Ph. Eur. member states or the EDQM (via its HelpDesk).

See also: